Follow-On Biologics Politics: AARP's Rother Explains "What Beat Us"
This article was originally published in The Pink Sheet Daily
Executive Summary
Brand companies' argument that longer exclusivity would create more jobs needs to be countered with additional research and advocacy on industrial policy, Rother says at GPhA's annual meeting in Florida.
You may also be interested in...
Pediatric Exclusivity For Brand Biologics Added In Senate FOB Provision, But Generics Have $1 Bil. In Leverage From CBO Score
The roll-out of the health care reform bill now under debate in the Senate is a good news/bad news event for the generic industry
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.